Incyte Corporation Stock News

Incyte <> has extended its post-market losses on Wednesday despite recording better than expected revenue for Q4 2021.Its blockbuster JAK inhibitor, JAKAFI/JAKAVI…

Incyte Corporation (NASDAQ:INCY) price is hovering lower on Wednesday, February 09, dropping -2.60% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at todays price movement shows that the recent level at last check reads $70.07, with intraday deals fluctuating between $67.90 These Numbers Show Just How Powerful Incyte Corporation (NASDAQ: INCY) Stock Is Read More »

Incyte (NASDAQ: INCY ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 0 1 0 1M Ago 0 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 0 0 These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of … Full story available on Benzinga.com

BEP, GTES, and INCY have been added to the Zacks Rank #5 (Strong Sell) List on February 9, 2022

Incyte Corporation''s (NASDAQ: INCY ) Q4 adjusted EPS reached $0.10 , compared to $0.93 posted a year ago. Analysts had estimated $0.86. Sales increased 9.3% Y/Y to $862.85 million, ahead of the consensus of $813.40 million. The Company''s operating expenses increased 20.3% to $752.12 million, with the cost of sales up 21%, R&D costs up 16%, and SG&A costs Full story available on Benzinga.com

Incyte Corporation (NASDAQ:INCY) Q4 2021 Earnings Conference Call February 8, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman,…

Incyte's (INCY) earnings miss, but revenues surpass estimates in the fourth quarter on higher royalty revenues and increased Jakafi sales.

Incyte press release (INCY): Q4 EPS of $0.10 may not be comparable to consensus of $0.86.Revenue of $862.5M (+9.2% Y/Y) beats by $49.12M.Total product and royalty revenues of $813…

Incyte Earnings Miss, Revenue Beats In Q4

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2021 Fourth Quarter and Year-end Financial Results and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

Incyte's (INCY) CEO Hervé Hoppenot on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell Pfizer (NYSE: PFE ) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. Karyopharm Therapeutics (NASDAQ: KPTI ) is likely to report quarterly loss at $0.49 per share on revenue of $50.49 million. Thomson Reuters (NYSE: TRI ) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.68 billion. Beasley Broadcast Group (NASDAQ: BBGI ) is likely to report quarterly earnings at $0.03 per share on revenue of $69.67 million. Willis Towers Watson (NASDAQ: WTW ) is projected to report quarterly earnings at $4.98 per share on revenue of $2.50 billion. Cenovus Energy (NYSE: CVE ) is expected to report quarterly earnings at $0.39 per share on revenue of $11.25 billion. Jacobs Engineering Group (NYSE: J ) is projected to report quarterly earnings at $1.58 per share on revenue of $3.51 billion. CTS (NYSE: CTS ) is estimated to report quarterly earnings at $0.47 per share on revenue of $122.96 million.

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.